Lupin launches generic joint pain drug in US market

The company's product -- Diclofenac Sodium Topical Solution 2 per cent -- is the generic version of Horizon Pharma Therapeutics Pennsaid, Lupin said in a statement. As per IQVIA MAT October 2022 data, Lupin said diclofenac sodium topical solution, 2 per cent, had estimated annual sales of USD 509 million in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CMjvEVz
via IFTTT